NSECertificate under SEBI (Depositories and Participants) Regulations, 201810 Jul 2026 · 10 Jul 2026, 11:08 am
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Mankind Pharma Limited · MANKIND
✦ AI SummaryRegulatory
Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialisation/rematerialisation of shares for the quarter ended June 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Attachments (1)
📄pdf
Download →
MANKIND1_10072026110849_Covering_letter_74.pdf
View document text
July 10, 2026
BSE Limited National Stock Exchange of India Limited
P J Towers, Exchange Plaza, C-1, Block G,
Dalal Street, Bandra Kurla Complex,
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Scrip Code: 543904 Symbol: MANKIND
Dear Sir/ Madam,
Subject: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants)
Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018,
kindly find enclosed herewith a copy of the certificate received from KFin Technologies
Limited, the Registrar and Share Transfer Agent of the Company for the quarter ended on June
30, 2026.
Request you to kindly take the above on record.
Thanking You,
Yours Faithfully,
For Mankind Pharma Limited
Hitesh Kumar Jain
Company Secretary &
Compliance Officer
Encl.: A/a
R:/KFIN/R74(5)
Date: 09.07.2026
THE COMPANY SECRETARY
MANKIND PHARMA LIMITED
236, OKHLA INDUSTRIAL ESTATE
PHASE – 3, NEW DELHI, 110020
Dear Sir(s),
Sub: Certificate under Regulation 74(5) of the Securities and Exchange Board of India
(Depositories & Participants) Regulations 2018 ('Regulations') for the quarter ended
June 30, 2026.
With reference to the above captioned Regulations, we hereby confirm that during the
period from April 01, 2026, to June 30, 2026, we have not received any requests for
dematerialisation/rematerialisation of shares of Mankind Pharma Limited, as required under
Regulation 74(5) of SEBI (Depositories and participants) Regulations 2018.
Thanking you,
Yours faithfully,
KFIN TECHNOLOGIES LIMITED
Dnyanesh Gharote
Vice President